- SciGen and DKSH have entered into a partnership for DKSH to supply Zometa® to Vietnam market. Once imported, the products will be distributed by local partners in Vietnam.
- Under the partnership DKSH will use their commercial footprint to expand access and availability of a key oncology medicine Zometa® in Vietnam
- SciGen will retain all international development responsibility for Zometa®, including regulatory and clinical development activities.
July 5, 2023, Vietnam – SciGen, a growing biopharmaceutical company, and DKSH, a leading Market Expansion Services provider, have entered a partnership for the supply of Zometa®, a lifesaving oncology medicine, to Vietnam. By way of this partnership SciGen’s Zometa® will be made available to a wider population base in Vietnam utilising DKSH’s strong market expansion and commercialisation capabilities. The products will be distributed by local distributors engaged by DKSH.
DKSH is a leading Market Expansion Services provider with nearly 160 years of experience, operating in 37 markets globally. With a tailor-made, comprehensive portfolio of services, the DKSH Business Unit Healthcare is a trusted healthcare solutions partner across Asia and beyond. The strategic partnership with DKSH plays an important part in Scigen’s expansion into Vietnam.
Zometa® (Zoledronic acid) is a bone-targeted agent for skeletal complications in advanced cancers and multiple myeloma. The product is manufactured at state of the art manufacturing facilities in Europe.
Dr. Shazli Ahmed Khan, SciGen’s Region Commercial Head for Asia Growth Markets, said: “SciGen is actively exploring expansion opportunities across Asia region with an objective to enhance access to its portfolio for the people who need them the most. Vietnam is a key market in SciGen’s Asian footprint and the organisation is committed to partner with the local healthcare organisations to achieve this objective for benefit of Vietnamese patients. July 5, 2023, marks a milestone for SciGen and DKSH’s partnership journey, to help Oncology patients together in Vietnam. At the forefront of this partnership remains a commitment to provide high-quality medicines and healthcare solutions to patients in Vietnam .”
Phillip Wray, General Director, DKSH Pharma Vietnam, said: “We are delighted to be a trusted partner to SciGen in expanding its business in Vietnam. By utilizing our global experience and local understanding, as well as collaboration with local distributors, we will share the same vision to improve accessibility of the high-quality oncology drug, Zometa, across Vietnam.”
For further information, please contact:
Zometa® (Zoledronic acid), a highly potent bone-targeted bisphosphonate, is an inhibitor of osteoclastic bone resorption.
Zometa® is indicated for the treatment of hypercalcemia of malignancy and prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumor-induced hypercalcemia) in patients with advanced malignancies involving bone.
SciGen is a rapidly growing biopharmaceutical company that markets and commercializes innovative and affordable healthcare products worldwide. We leverage our commercialization and networking capabilities to in-licenses and distribute branded pharmaceutical products and medical devices to treat endocrinological and oncological diseases, and continuously fill and improve our pipeline and product portfolio. Founded in the Asian Innovation Capital, Singapore in 1988, we currently have operations in Singapore, South Korea, Australia, China, Philippines and present commercially in all 6 continents. With the exceptional commercialization capabilities, regulatory expertise as well as international management experiences, and strategic partnerships built with industry and academic institutes, we strive to deliver hope and make a real and lasting difference to patients and their families. To learn more about SciGen, visit: www.scigen.com
DKSH’s purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 37 markets with 32,600 specialists, generating net sales of CHF 11.3 billion in 2022. The DKSH Business Unit Healthcare is a trusted healthcare solutions partner across Asia and beyond. With around 7,990 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2022. www.dksh.com/hec